Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4
Index Copernicus  – 168.52; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/166656

Publication type: meta-analysis

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:


Shao Y, Shao F, Zhou J, Fang S, Zhu J, Li F. The association between hypoglycemia and mortality in sepsis and septic shock: A systematic review and meta-analysis [published online as ahead of print on June 30, 2023]. Adv Clin Exp Med. 2024. doi:10.17219/acem/166656

The association between hypoglycemia and mortality in sepsis and septic shock: A systematic review and meta-analysis

Yuping Shao1,A,D,F, Feng Shao2,B,C,F, Jie Zhou1,B,C,F, Shunjin Fang1,B,C,F, Jianfeng Zhu1,B,C,F, Fangfang Li3,E,F

1 Department of Critical Care Medicine, Huzhou Third Municipal Hospital, Affiliated Hospital of Huzhou University, China

2 Department of Rheumatology, Huzhou Third Municipal Hospital, Affiliated Hospital of Huzhou University, China

3 Department of Hospital Infection Management, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, China

Graphical abstract


Graphical abstracts

Abstract

Over 48 million cases of sepsis and 11 million sepsis-related deaths were reported in 2017, making it one of the leading causes of mortality. This meta-analysis compared mortality risk among patients with sepsis or septic shock and associated hypoglycemia or euglycemia on admission by searching for observational studies in PubMed, Embase and Scopus databases. The eligible studies included patients with sepsis and/or severe sepsis/septic shock and compared mortality rates between those with hypoglycemia on admission and those who were euglycemic. A stratified analysis based on sepsis or severe sepsis/septic shock and diabetes on admission included 14 studies. Patients with hypoglycemia had a significantly higher risk of in-hospital mortality and mortality during the 1st month after discharge. In addition, hypoglycemic patients with sepsis had a slightly increased risk of in-hospital mortality, but no increase in the mortality risk was observed within 1 month of follow-up. However, in patients with severe sepsis and/or septic shock, hypoglycemia was associated with a higher risk of both in-hospital mortality and mortality during 1 month of follow-up. In patients with diabetes, hypoglycemia was not associated with an increased risk of in-hospital mortality or mortality within 1 month of follow-up. Patients with sepsis or severe sepsis/septic shock and hypoglycemia had an increased mortality risk, and the association was stronger in cases of severe sepsis/septic shock. Hypoglycemia in diabetic patients did not correlate with increased mortality risk. Careful monitoring of blood glucose in sepsis and/or severe sepsis/septic shock patients is required.

Key words: sepsis, severe sepsis, septic shock, blood glucose, hypoglycemia, mortality, meta-analysis

Introduction

Over 48 million cases of sepsis and 11 million sepsis-related deaths were reported in 2017, making it one of the leading causes of mortality.1 Data from Europe, North America and Australia show that 30-day and 90-day mortality rates due to sepsis were 25% and 32%, respectively.2 The highest sepsis burden and related mortality were found in Sub-Saharan Africa and Southeast Asia.1

Due to changes in endocrinal metabolism, patients with sepsis and/or septic shock have fluctuations in blood glucose levels that negatively impact the internal milieu and worsen their clinical condition.3, 4 Sepsis is associated with higher levels of oxidative stress and the secretion of interleukin (IL)-1, IL-6 and tumor necrosis factor alpha (TNF-α) by inflammatory cells. This, in turn, damages pancreatic β-cells,3, 4, 5 affects the production of insulin, and leads to a state of stress hyperglycemia.5 Hyperglycemia may result in several complications, such as increased predisposition to infections, oxidative stress and increased mortality risk.6, 7 However, studies have also indicated that patients with sepsis and/or septic shock are at an increased risk of hypoglycemia,5, 8 though its mechanisms are still unclear. Some studies suggest that the increased utilization of peripheral glucose, depletion of glycogen reserves, reduction in gluconeogenesis, and a comparatively decreased nutrient supply may play a role in sepsis-induced hypoglycemia.5, 9, 10 Another crucial contributor could be the strict measures for blood glucose control in such patients.11

The effect of hypoglycemia on the survival of patients with sepsis is still unclear. Although studies have examined the impact of hypoglycemia on the mortality of these patients, only a few have summarized the available data.12, 13 A meta-analysis by Wang et al. pooled findings from 5 studies and found increased mortality in patients with decreased blood glucose levels.12 Recently, several new studies provided updated clinical evidence, and these findings should also be considered.

Objectives

The primary objective of this meta-analysis was to synthesize evidence from available studies to estimate the risk of mortality in patients with sepsis and/or septic shock and associated hypoglycemia at the time of hospital admission.

Materials and methods

Database search and strategy

We searched PubMed, Embase and Scopus databases for English-language papers published until April 30, 2022, using the following key words: (“hypoglycaemia” OR “hypoglycemia” OR “low blood glucose” OR “low blood sugar”) AND (“sepsis” OR “severe sepsis” OR “septic shock” OR “septicemia”) AND (“mortality” OR “death” OR “survival”). We based our review on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,14 and the paper was registered at PROSPERO with the number CRD42022336895.

Study selection criteria and process

Observational studies with either retrospective or prospective designs concerning subjects with sepsis and/or severe sepsis/septic shock were considered. Furthermore, the analyzed studies had to compare the mortality risk among patients with hypoglycemia or euglycemia at the time of hospital admission. We excluded case reports and review articles, as well as studies that did not have the exposure of interest (blood glucose assessment at the time of admission) or did not compare the risk of mortality between hypoglycemic and euglycemic patients.

After removing duplicates, the list of potentially eligible studies was screened by 2 independent reviewers following pre-defined inclusion and exclusion criteria. The articles that met the inclusion criteria were subject to a full-text assessment. Any disagreements between the 2 reviewers were resolved by discussion. The bibliography of the included studies was thoroughly screened for additional relevant publications. The study selection process is shown in Figure 1.

Data extraction and statistical analysis

We used a pretest data extraction sheet to fill in relevant data from the included studies. The data extraction process was carried out independently by 2 authors. The quality of the studies was assessed using the Newcastle-Ottawa Quality Assessment Scale for observational studies.15 Statistical analysis employed STATA software v. 16.0 (StataCorp LLC, College Station, USA). The pooled effect sizes and 95% confidence intervals (95% CIs) were reported as odds ratios (ORs). The selection of the final analytical model was based on the observed I2 value (used to denote the degree of heterogeneity). We used a random effects model for outcomes with I2 > 40%, and a fixed effects model was used for I2 ≤ 40%.16 Egger’s test assessed publication bias.17 Wherever reported, we considered a p-value of less than 0.05 to denote statistical significance. We used the method reported by Chyou to calculate the p-value for the reported pooled effect sizes in the meta-analysis.18 First, we calculated the standardized z statistic using the following formula: z = (b/sb), where b = log (OR) and sb = ln (upper confidence limit/OR)/1.96. Second, we derived p-values corresponding to the obtained z-statistic and reported the z-statistic and its corresponding p-value in the results. A subgroup analysis based on the clinical condition studied, i.e., sepsis or severe sepsis/septic shock, as well as the presence or absence of diabetes on admission, was also carried out.

Results

A total of 14 studies were selected for this meta-analysis.19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 The specific details of the included studies are summarized in Table 1. All studies were observational, including 12 retrospective and 2 prospective in design. Three studies were conducted in Japan and Australia. Two studies were from Taiwan and the USA, and China, Uganda and South Korea conducted 1 study each. Eight studies included patients with severe sepsis and/or septic shock, and 6 included patients with sepsis. There was a difference in the operational definition adopted for the classification of hypoglycemia in the included studies. Supplementary Tables 2 and 3 summarize the findings of the quality assessment of the 14 included studies. All studies were of moderate to good quality.

Hypoglycemia and mortality risk

The pooled findings suggested an increased risk of in-hospital mortality (OR = 1.40, 95% CI: 1.18–1.65, I2 = 88.2%, n = 12, z-statistic = 4.25, p = 0.0001) and mortality within 1 month of hospital discharge (OR = 4.01, 95% CI: 2.11–7.65, I2 = 76.7%, n = 5, z-statistic = 4.21, p = 0.0001) among patients with hypoglycemia compared to patients with euglycemia (Figure 2). There was no evidence of publication bias (p > 0.05) for mortality outcomes at either timepoint (Supplementary Table 3).

Analysis based on the presence of sepsis or severe sepsis/septic shock

In patients with sepsis, hypoglycemia was not significantly correlated with a higher risk of in-hospital mortality (OR = 1.15, 95% CI: 1.00–1.32, I2 = 88.1%, n = 4, z-statistic = 1.99, p = 0.05) or with an increased risk for mortality within 1 month of follow-up (OR = 4.52, 95% CI: 0.74–27.7, I2 = 91.0%, n = 2, z-statistic = 1.64, p = 0.10), compared to euglycemic patients (Figure 3). In patients with severe sepsis and/or septic shock, hypoglycemia was associated with a significantly higher risk of in-hospital mortality (OR = 1.64, 95% CI: 1.20–2.25, I2 = 58.1%, n = 8, z-statistic = 3.06, p = 0.002) and mortality within 1 month of follow-up (OR = 3.94, 95% CI: 1.96–7.89, I2 = 53.2%, n = 3, z-statistic = 3.88, p = 0.0001) (Figure 4), with no evident publication bias (p > 0.05) (Supplementary Table 3).

Analysis of patients with diabetes at the time of admission

In patients who were diabetic at the time of admission, hypoglycemia did not correlate with increased in-hospital mortality risk (OR = 1.45, 95% CI: 0.79–2.66, I2 = 92.3%, n = 4, z-statistic = 1.19, p = 0.23) or mortality within 1 month of follow-up (OR = 1.34, 95% CI: 0.84–2.16, I2 = 0.0%, n = 2, z-statistic = 1.16, p = 0.25) (Figure 5), with no evident publication bias (p > 0.05) for any of these 2 outcomes (Supplementary Table 3).

Discussion

The findings of the current review showed a higher mortality risk in patients with hypoglycemia, and this risk was predominant in patients with severe sepsis and/or septic shock. However, hypoglycemia was not associated with a higher mortality risk in patients with pre-existing diabetes. These findings are consistent with a previous review by Wang et al., where a similar association of hypoglycemia with mortality was noted (OR = 1.68).12 Similarly, the association between mortality and hyperglycemia was stronger in patients with severe sepsis/septic shock (OR = 1.98).

Previous studies showed that patients with severe infection/sepsis usually have elevated blood glucose levels (stress hyperglycemia) due to the enhanced release of glucocorticoids, epinephrine and norepinephrine.33, 34, 35 These higher glucose levels may lead to an inflammatory state, endothelial cell dysfunction, oxidative stress, and immunosuppression.34, 35, 36 Studies have also noted an increased risk of mortality in patients with hyperglycemia and associated sepsis.6, 7, 37 However, there is also a possible risk of hypoglycemia due to either strict glycemic control strategies or the upregulation of cytokines that increase the utilization of peripheral blood glucose and downregulate gluconeogenesis.5, 8, 9, 10, 11 Additionally, the metabolic rate in patients with sepsis is higher, which may lead to excessive glucose consumption and glycogen reserve depletion.5, 38, 39 Another vital pathway through which hypoglycemia may occur in patients with sepsis is the inhibition of the pro-secretory effects of adrenocorticotropic hormone (ACTH) on adrenal cortisol production,39, 40 leading to corticosteroid insufficiency.39, 40

Hypoglycemia may lead to the activation of sympathoadrenal mechanisms, abnormal cardiac repolarization, dysregulation of hemostatic mechanisms such as accelerated thrombogenesis and vasoconstriction, and elevated levels of inflammatory cytokines.41 All of these processes could worsen the outcome for patients with sepsis. The higher mortality risk, especially in patients with severe sepsis/septic shock, could be due to increased glycemic variability, as documented in some studies.42, 43 The current meta-analysis found no significant association between hypoglycemia and mortality among diabetic patients, which is contrary to the findings of a meta-analysis by Wang et al. showing that hypoglycemia (defined as a blood glucose level of <145 mg/dL) correlated with increased mortality risk in patients with diabetes and associated sepsis.13 The authors suggested that this could be due to the relative intolerance in diabetic subjects to hypoglycemic episodes.12, 23 The noted difference in the findings could be partially explained by the difference in the cutoff level defining hypoglycemia. Most studies included in the current meta-analysis adopted a comparatively lower cutoff level. These contrasting findings underscore the complex nature of the interactions between blood glucose levels and adverse clinical outcomes among patients with pre-existing diabetes and call for more research on this issue.

Limitations

Our study had some limitations. First, all included studies were observational, meaning that a causal relationship could not be established between hypoglycemia and mortality. Furthermore, there is a possibility that crucial variables and confounders were not adjusted for, or data on these variables were not collected. Second, there was a high heterogeneity in the findings, which could be due to the differences in methodologies and variation in the participant characteristics. The included studies used various blood sugar cutoff values for hypoglycemia, and there were differences in the operational definitions adopted for sepsis. We conducted our analysis using a random effects model to partly address the high heterogeneity.

Conclusions

Our findings indicate that hypoglycemia might correlate with increased mortality risk in sepsis and/or severe sepsis/septic shock patients. Therefore, monitoring of blood glucose in these patients may be required. We noted that different blood sugar cutoff values were used to label hypoglycemia for both euglycemic and diabetic patients. It is important to develop harmonized diagnostic criteria that are reliable and practical enough to be implemented routinely in order to avoid such heterogeneity. Such criteria need to be updated when new evidence becomes available, with new developments necessitating changes in the criteria for sepsis informed by findings from prospectively conducted studies. More research is needed to clarify the link between low blood glucose levels and the mortality risk in sepsis patients with diabetes.

Supplementary data

The supplementary materials are available at https://doi.org/10.5281/zenodo.7967501. The package contains the following files:

Supplementary Table 1. Authors’ judgements about study quality using the adapted Newcastle-Ottawa risk of bias assessment tool.

Supplementary Table 2. Authors’ judgements about study quality using the adapted Newcastle-Ottawa risk of bias assessment tool.

Supplementary Table 3. Results of Egger’s test for the outcomes.

Tables


Table 1. Characteristics of the studies included in the meta-analysis

Author, year, reference

Study design

Country

Characteristics of the participants

Operational definition for hypoglycemia

Sample size

Outcome (mortality) (hypoglycemia compared to euglycemia)

Furukawa et al. (2019)19

retrospective

Japan

patients included in the study had sepsis; mean age: 74 years; males: 61%; infection focus (pneumonitis: 53%; pyelonephritis: 16%)

blood glucose on admission: <80 mg/dL

336

in-hospital: OR: 3.50 (95% CI: 1.78–6.94)

Mitsuyama et al. (2022)20

retrospective

Japan

patients included in the study had sepsis; median age: 71 years; males: 63%; infection focus (lung: 38%; abdomen: 23%; skin and soft tissue: 17%); pre-existing diabetes: 26%, hypertension: 34%

blood glucose on admission: ≤70 mg/dL

265

day 28: OR: 12.18 (95% CI: 4.35–34.2)

Wei et al. (2021)21

retrospective

China

patients included in the study had sepsis; mean age: approx. 65 years; males: 55%; hypertension: 30%, chronic heart disease: 10%, chronic kidney disease: 13%

blood glucose on admission: <70 mg/dL

2948

day 30: OR: 1.91 (95% CI: 1.35–2.72);

with diabetes on admission, day 30: OR: 1.40 (95% CI: 0.86–2.29)

Chan et al. (2016)22

retrospective

Taiwan

patients included in the study had severe sepsis; median age: approx. 74 years; males: 79%; primary reason for sepsis (pneumonia: 83%); mean APACHE II score: 27

blood glucose on admission: <80 mg/dL

127

in-hospital: OR: 3.60 (95% CI: 1.24–10.50)

day 14: OR: 6.81 (95% CI: 2.43–19.1)

with diabetes on admission, day 14: OR: 0.70 (95% CI: 0.10–4.87)

Schuetz et al. (2011)23

prospective

USA

majority of patients included in the study had sepsis (57.5%); mean age: 59 years; males: 49%; white race: 70%; associated diabetes: 24%; associated prior congestive heart failure: 10%

blood glucose on admission: <100 mg/dL

7754

in-hospital: OR: 1.09 (95% CI: 1.03–1.14)

with diabetes on admission, in-hospital: OR: 2.30 (95% CI: 1.61–3.30)

Ssekitoleko et al. (2011)24

prospective

Uganda

patients included in the study had severe sepsis; mean age: approx. 35 years; males: 46%; bacteremia/fungemia present in 21%; HIV-positive: 83%

blood glucose on admission: <80 mg/dL

418

in-hospital: OR: 1.60 (95% CI: 0.92–2.78)

Park et al. (2012)25

retrospective

South Korea

patients included in the study had septic shock (around 60%); mean age: approx. 70 years; males: 53%; associated diabetes: 33%: insulin therapy: 70%; bacteremia/fungemia present in 21%; HIV-positive: 83%

blood glucose on admission: <40 mg/dL

313

in-hospital: OR: 6.37 (95% CI: 2.31–17.55)

day 30: OR: 5.30 (95% CI: 2.04–13.78)

1 year: OR: 6.48 (95% CI: 1.89–22.21)

Magee et al. (2018)26

retrospective

Australia

patients included in the study with sepsis; mean age: approx. 66 years; males: 56%; associated chronic renal failure: 6%; immunosuppression: 9%; APACHE III mean score: approx. 66

blood glucose on admission: <120 mg/dL

90,644

in-hospital: OR: 0.99 (95% CI: 0.95–1.04)

with diabetes on admission, in-hospital: OR: 1.71 (95% CI: 1.36–2.14)

Kushimoto et al. (2020)27

retrospective

Japan

majority of patients included in the study had severe sepsis/septic shock; mean age: approx. 73 years; males: 60%; mean BMI: 22 kg/m2; associated diabetes: 23%; site of infection (lung: 31%, abdomen: 26%)

blood glucose on admission: <70 mg/dL

1158

in-hospital: OR: 2.06 (95% CI: 1.22–3.50)

day 28: OR: 2.37 (95% CI: 1.38–4.08)

with diabetes on admission, in-hospital: OR: 1.71 (95% CI: 0.51–5.72)

Chao et al. (2017)28

retrospective

Taiwan

patients included in the study had sepsis; median age: approx. 66 years; males: 54%; associated diabetes: 58%; chronic kidney disease: 12%

blood glucose on admission: ≤100 mg/dL

6165

in-hospital: OR: 1.39 (95% CI: 1.08–1.78)

with diabetes on admission, in-hospital: OR: 0.74 (95% CI: 0.59–0.93)

Bagshaw et al. (2009)29

retrospective

Australia

majority of patients included in the study had severe sepsis/septic shock; mean age: approx. 65 years; males: 59%

blood glucose on admission: <72 mg/dL

66,184

in-hospital: OR: 1.60 (95% CI: 1.40–1.80)

Liang and Ty (2018)30

retrospective

USA

patients included in the study had severe sepsis and/or septic shock; age >18 years; patients with DKA or hyperosmolar hyperglycemic state were excluded from the study

blood glucose on admission: <140 mg/dL

150

in-hospital: OR: 0.65 (95% CI: 0.29–1.46)

Shahab et al. (2011)31

retrospective

no data provided

patients included in the study had severe sepsis and/or septic shock; patients with DKA and/or hyperosmolar nonketotic comma were excluded from the study

blood glucose on admission: <150 mg/dL

115

in-hospital: OR: 1.08 (95% CI: 0.48–2.45)

Tiruvoipati et al. (2013)32

retrospective

Australia

patients included in the study had severe sepsis and/or septic shock; mean age: 67 years; males: 50%; mean APACHE III score: 75; 16% with associated chronic renal failure and 20% with diabetes mellitus

blood glucose on admission: ≤124 mg/dL

297

in-hospital: OR: 1.20 (95% CI: 0.64–2.23)
APACHE II – Acute Physiology and Chronic Health Evaluation II; HIV – human immunodeficiency virus; DKA – diabetic ketoacidosis; OR – odds ratio; 95% CI – 95% confidence interval; BMI – body mass index.

Figures


Fig. 1. The selection process of the studies included in the review
Fig. 2. Mortality risk in patients with sepsis or severe sepsis/septic shock and associated hypoglycemia, compared to those with euglycemia at the time of admission
OR – odds ratio; 95% CI – 95% confidence interval.
Fig. 3. Mortality risk in patients with sepsis and associated hypoglycemia, compared to those with euglycemia at the time of admission
OR – odds ratio; 95% CI – 95% confidence interval.
Fig. 4. Mortality risk in patients with severe sepsis/septic shock and associated hypoglycemia, compared to those with euglycemia at the time of admission
OR – odds ratio; 95% CI – 95% confidence interval.
Fig. 5. Mortality risk in diabetic subjects with associated hypoglycemia, compared to those with euglycemia on admission

References (43)

  1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
  2. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019: Results from a systematic review and meta-analysis. Crit Care. 2020;24(1):239. doi:10.1186/s13054-020-02950-2
  3. Ingels C, Gunst J, Van den Berghe G. Endocrine and metabolic alterations in sepsis and implications for treatment. Crit Care Clin. 2018;34(1):81–96. doi:10.1016/j.ccc.2017.08.006
  4. Khardori R, Castillo D. Endocrine and metabolic changes during sepsis: An update. Med Clin North Am. 2012;96(6):1095–1105. doi:10.1016/j.mcna.2012.09.005
  5. Wasyluk W, Zwolak A. Metabolic alterations in sepsis. J Clin Med. 2021;10(11):2412. doi:10.3390/jcm10112412
  6. Yao RQ, Ren C, Wu GS, Zhu YB, Xia ZF, Yao YM. Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis. Int J Biol Sci. 2020;16(9):1658–1675. doi:10.7150/ijbs.43447
  7. van Vught LA, Wiewel MA, Klein Klouwenberg PMC, et al. Admission hyperglycemia in critically ill sepsis patients: Association with outcome and host response. Crit Care Med. 2016;44(7):1338–1346. doi:10.1097/CCM.0000000000001650
  8. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock. 2000;13(5):379–385. doi:10.1097/00024382-200005000-00006
  9. Dendoncker K, Libert C. Glucocorticoid resistance as a major drive in sepsis pathology. Cytokine Growth Factor Rev. 2017;35:85–96. doi:10.1016/j.cytogfr.2017.04.002
  10. Weis S, Carlos AR, Moita MR, et al. Metabolic adaptation establishes disease tolerance to sepsis. Cell. 2017;169(7):1263–1275.e14. doi:10.1016/j.cell.2017.05.031
  11. Hirasawa H, Oda S, Nakamura M. Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol. 2009;15(33):4132. doi:10.3748/wjg.15.4132
  12. Wang J, Zhu CK, Yu JQ, Tan R, Yang PL. Hypoglycemia and mortality in sepsis patients: A systematic review and meta-analysis. Heart Lung. 2021;50(6):933–940. doi:10.1016/j.hrtlng.2021.07.017
  13. Wang W, Chen W, Liu Y, et al. Blood glucose levels and mortality in patients with sepsis: Dose–response analysis of observational studies. J Intensive Care Med. 2021;36(2):182–190. doi:10.1177/0885066619889322
  14. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PRISMA 2020 checklist. 2020. http://www.prisma-statement.org/. Accessed May 10, 2022.
  15. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa, Canada: Ottawa Hospital Research Institute; 2021. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 14, 2022.
  16. Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Hoboken, USA: John Wiley & Sons; 2019. doi:10.1002/9781119536604
  17. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
  18. Chyou PH. A simple and robust way of concluding meta-analysis results using reported p-values, standardized effect sizes, or other statistics. Clin Med Res. 2012;10(4):219–223. doi:10.3121/cmr.2012.1068
  19. Furukawa M, Kinoshita K, Yamaguchi J, Hori S, Sakurai A. Sepsis patients with complication of hypoglycemia and hypoalbuminemia are an early and easy identification of high mortality risk. Intern Emerg Med. 2019;14(4):539–548. doi:10.1007/s11739-019-02034-2
  20. Mitsuyama Y, Shimizu K, Komukai S, et al. Sepsis‐associated hypoglycemia on admission is associated with increased mortality in intensive care unit patients. Acute Med Surg. 2022;9(1):e718. doi:10.1002/ams2.718
  21. Wei X, Min Y, Yu J, et al. Admission blood glucose is associated with the 30-days mortality in septic patients: A retrospective cohort study. Front Med (Lausanne). 2021;8:757061. doi:10.3389/fmed.2021.757061
  22. Chan MC, Tseng JS, Hsu KH, et al. A minimum blood glucose value less than or equal to 120 mg/dL under glycemic control is associated with increased 14-day mortality in nondiabetic intensive care unit patients with sepsis and stress hyperglycemia. J Crit Care. 2016;34:69–73. doi:10.1016/j.jcrc.2016.04.002
  23. Schuetz P, Jones AE, Howell MD, et al. Diabetes is not associated with increased mortality in emergency department patients with sepsis. Ann Emerg Med. 2011;58(5):438–444. doi:10.1016/j.annemergmed.2011.03.052
  24. Ssekitoleko R, Jacob ST, Banura P, et al. Hypoglycemia at admission is associated with inhospital mortality in Ugandan patients with severe sepsis. Crit Care Med. 2011;39(10):2271–2276. doi:10.1097/CCM.0b013e3182227bd2
  25. Park S, Kim DG, Suh G, et al. Mild hypoglycemia is independently associated with increased risk of mortality in patients with sepsis: A 3-year retrospective observational study. Crit Care. 2012;16(5):R189. doi:10.1186/cc11674
  26. Magee F, Bailey M, Pilcher DV, Mårtensson J, Bellomo R. Early glycemia and mortality in critically ill septic patients: Interaction with insulin-treated diabetes. J Crit Care. 2018;45:170–177. doi:10.1016/j.jcrc.2018.03.012
  27. Kushimoto S, Abe T, Ogura H, et al; on behalf of JAAM FORECAST group. Impact of blood glucose abnormalities on outcomes and disease severity in patients with severe sepsis: An analysis from a multicenter, prospective survey of severe sepsis. PLoS One. 2020;15(3):e0229919. doi:10.1371/journal.pone.0229919
  28. Chao HY, Liu PH, Lin SC, et al. Association of in-hospital mortality and dysglycemia in septic patients. PLoS One. 2017;12(1):e0170408. doi:10.1371/journal.pone.0170408
  29. Bagshaw SM, Egi M, George C, Bellomo R. Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med. 2009;37(2):463–470. doi:10.1097/CCM.0b013e318194b097
  30. Liang M, Ty P. Abstract1511: Impact of varying ICU hyperglycemia severities on sepsis mortality. Crit Care Med. 2018;46(1):739. doi:10.1097/01.ccm.0000529513.81407.a4
  31. Shahab L, Soufi S, Al-Hamad S, Shibli M. The outcome of glycemic control in critically ill septic patients. Chest. 2011;140(4):327A. doi:10.1378/chest.1116700
  32. Tiruvoipati R, Chiezey B, Lewis D, et al. Stress hyperglycemia may not be harmful in critically ill patients with sepsis. Surv Anesthesiol. 2013;57(1):5–6. doi:10.1097/01.SA.0000424053.09290.f1
  33. Bar-Or D, Rael LT, Madayag RM, et al. Stress hyperglycemia in critically ill patients: Insight into possible molecular pathways. Front Med (Lausanne). 2019;6:54. doi:10.3389/fmed.2019.00054
  34. Leonidou L, Michalaki M, Leonardou A, et al. Stress-induced hyperglycemia in patients with severe sepsis: A compromising factor for survival. Am J Med Sci. 2008;336(6):467–471. doi:10.1097/MAJ.0b013e318176abb4
  35. Schmoch T, Uhle F, Siegler BH, et al. The glyoxalase system and methyl­glyoxal-derived carbonyl stress in sepsis: Glycotoxic aspects of sepsis pathophysiology. Int J Mol Sci. 2017;18(3):657. doi:10.3390/ijms18030657
  36. Yu WK. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol. 2003;9(8):1824. doi:10.3748/wjg.v9.i8.1824
  37. Fabbri A, Marchesini G, Benazzi B, et al. Stress hyperglycemia and mortality in subjects with diabetes and sepsis. Crit Care Explor. 2020;2(7):e0152. doi:10.1097/CCE.0000000000000152
  38. Kreymann G, Grosser S, Buggisch P, Gottschall C, Matthaei S, Greten H. Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. Crit Care Med. 1993;21(7):1012–1019. doi:10.1097/00003246-199307000-00015
  39. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med. 2006;174(12):1319–1326. doi:10.1164/rccm.200509-1369OC
  40. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock: An update. Front Endocrinol (Lausanne). 2016;7:70. doi:10.3389/fendo.2016.00070
  41. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418. doi:10.1056/NEJMoa1003795
  42. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 2006;105(2):244–252. doi:10.1097/00000542-200608000-00006
  43. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, DeVries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38(3):838–842. doi:10.1097/CCM.0b013e3181cc4be9
© Wroclaw Medical University